Cargando…

Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis

OBJECTIVE: Soluble Tumor Necrosis Factor Receptor II (sTNFR2) is used as a biomarker to study cardiovascular disease (CVD) in diverse populations. TNF inhibitors (TNFi's) are a common treatment for inflammatory conditions. The objective of this study was to examine whether TNFi use impacts meas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Nicole, Huang, Jie, Frits, Michelle, Iannaccone, Christine, Weinblatt, Michael E., Rifai, Nader, Shadick, Nancy, Bradwin, Gary, Liao, Katherine P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527918/ https://www.ncbi.nlm.nih.gov/pubmed/31193412 http://dx.doi.org/10.1016/j.plabm.2019.e00122

Ejemplares similares

Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005)

The Association Between Reduction in Inflammation and Changes in Lipoprotein Levels and HDL Cholesterol Efflux Capacity in Rheumatoid Arthritis
por: Liao, Katherine P., et al.
Publicado: (2015)

Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)

Validity of the Nurses’ health study physical activity questionnaire in estimating physical activity in adults with rheumatoid arthritis
por: Quinn, Thomas, et al.
Publicado: (2017)

Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor
por: Aberumand, Babak, et al.
Publicado: (2014)

Sustained rheumatoid arthritis remission is uncommon in clinical practice
por: Prince, Femke HM, et al.
Publicado: (2012)

Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis
por: Martínez-Santana, Virginia, et al.
Publicado: (2013)

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis
por: Perpétuo, Inês P., et al.
Publicado: (2017)

The Impact of Exercise, Lifestyle, and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study
por: Shadick, Nancy A., et al.
Publicado: (2019)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use
por: Lim, Mie Jin, et al.
Publicado: (2014)

Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort
por: Ahmad, Harris A., et al.
Publicado: (2018)

Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study
por: Lee, Yvonne C, et al.
Publicado: (2011)

Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors
por: Tanaka, Toshio, et al.
Publicado: (2014)

Tumor Necrosis Factor Inhibition and Head and Neck Cancer Recurrence and Death in Rheumatoid Arthritis
por: Phillips, Christopher, et al.
Publicado: (2015)

Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis
por: Reams, Jennifer, et al.
Publicado: (2020)

Characterization and Function of Tumor Necrosis Factor and Interleukin‐6–Induced Osteoclasts in Rheumatoid Arthritis
por: Yokota, Kazuhiro, et al.
Publicado: (2021)

Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis
por: Desai, Rishi J., et al.
Publicado: (2014)

Development of Rheumatoid Nodules after Anti-Tumor Necrosis Factor-α Treatment with Adalimumab for Rheumatoid Arthritis
por: Shin, Sungsik, et al.
Publicado: (2016)

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
Publicado: (1992)

Tumor necrosis factor α-induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis
por: Inoue, Asuka, et al.
Publicado: (2009)

Upregulation of tumor necrosis factor receptor-associated factor 6 correlated with synovitis severity in rheumatoid arthritis
por: Zhu, Lang-Jing, et al.
Publicado: (2012)

Acquired Factor VIII Inhibitor in a Patient of Rheumatoid Arthritis on Tumor Necrosis Factor Inhibitor Therapy
por: Mori, Tomoyo, et al.
Publicado: (2018)

Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia
por: Lee, Yvonne C., et al.
Publicado: (2016)

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
por: Alonso-Ruiz, Alberto, et al.
Publicado: (2008)

Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy
por: Leboime, Ariane, et al.
Publicado: (2009)

Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
por: Kang, Ji-Hyoun, et al.
Publicado: (2014)

Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis
por: Fisher, Anat, et al.
Publicado: (2016)

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
por: Low, Audrey S. L., et al.
Publicado: (2016)

Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?
por: Huang, Ying, et al.
Publicado: (2019)

Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review
por: Davignon, Jean-Luc, et al.
Publicado: (2018)

Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis
por: Park, Siyeon, et al.
Publicado: (2019)

Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
por: Julià, Antonio, et al.
Publicado: (2021)

Tumor Necrosis Factor-Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis: A Systematic Review
por: Nair, Shaalina, et al.
Publicado: (2022)

Changes in Bone Metabolism in Patients with Rheumatoid Arthritis during Tumor Necrosis Factor Inhibitor Therapy
por: Janković, Tanja, et al.
Publicado: (2023)

The effect of capsaicin on circulating biomarkers, soluble tumor necrosis factor and soluble tumor necrosis factor-receptor-1 and -2 levels in vivo using lipopolysaccharide-treated mice
por: Ijiri, Yoshio, et al.
Publicado: (2014)

Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor
Publicado: (1986)

Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis
por: Hayashi, Shinya, et al.
Publicado: (2020)

Resistance of rheumatoid arthritis synovial fibroblasts to p38 MAP-kinase inhibition of pro-destructive functions mediated by tumor necrosis factor alpha/tumor necrosis factor receptor-1
por: Kunisch, E, et al.
Publicado: (2005)

Association between tumor necrosis factor polymorphisms and rheumatoid arthritis as well as systemic lupus erythematosus: a meta-analysis
por: Chen, Lin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6hmn50qhn5s5hv6eglsvrdd2jk